Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
April 8 2022: Reykjavik, Iceland — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE: ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab) in the United States. The settlement grants Alvotech a license entry date in the United States of July 1, 2023.
Access to content from the Arctic Knowledge Archives is available to Passport holders only.
Arctic Today is a non-profit organization, supported by donations from readers like you. While we strongly believe in giving free access to current news for all readers, we reserve content older than one year for our supporters. All individual contributions of at least $15/month or $150/year will receive a Passport to the Arctic Knowledge Archives. Help us drive the leading non-profit editorial team dedicated to delivering context, information and analysis about events in the Arctic.
Already have a Passport? Sign in
choose your level of support and unlock your Arctic Passport.
Individual Annual
$1.00
Year
Individual Monthly
$15.00
Month
